Calculating the dose of cisplatin that is actually utilized in hyperthermic intraperitoneal chemotherapy among ovarian cancer patients

Table 3 Linear regression model results for actually utilized dose of cisplatin

	β	95% CI for β	P value	β	95% CI for β	P value
Age (years)	−0.012	−0.169, 0.146	0.881	–	–	–
BMI (kg/m²)	−0.117	−0.705, 0.472	0.693	–	–	–
Serum creatinine prior to HIPEC (umol/l)	0.013	−0.103, 0.129	0.822	–	–	–
Serum albumin (g/l) prior to HIPEC	0.078	−0.308, 0.464	0.689	–	–	–
TD (mg)	0.777	0.554, 1.000	< 0.001	0.667	0.500, 0.833	< 0.001
V_Pretained (ml)	−0.012	−0.016, − 0.008	< 0.001	0.010	−0.013, − 0.007	< 0.001

BMI Body mass index, HIPEC Hyperthermic intraperitoneal chemotherapy, TD Total dose, V_Pretained Volume (ml) of the perfusate that was retained in the treatment system at the end of hyperthermic intraperitoneal chemotherapy;

ISSN: 1757-2215